MOLOGEN AG is a biotechnology company researching and developing innovative DNA-based drugs to fight diseases that require a high degree of medical treatment.
The company’s activities are concentrated on creating new immunological drugs and therapies to combat cancer and on developing state-of-the-art vaccines for the prevention and the treatment of serious infectious diseases in humans as well as animals.
MOLOGEN’s innovative approach focuses on research and development of medicines based on DNA structures (DNA: deoxyribonucleic acid). The patented DNA-based platform technologies MIDGE® and dSLIM® offer a universal foundation and provide a wide range of possible applications.
In the fight against cancer, product candidates to combat colorectal carcinoma (CRC) and renal cell carcinoma (RCC) are at the forefront of today’s preclinical and clinical developments. MOLOGEN uses its two platform technologies to achieve optimum treatment results. Thanks to the central role played by the company’s founders in the first gene therapy clinical studies conducted in
The DNA vaccine against Leishmania infection (leishmaniasis) is the most advanced in the field of vaccine development. This and the other MOLOGEN AG vaccine candidates result from unique properties displayed by the MIDGE® technology, for which the company received the renowned “Frost & Sullivan 2006 Technology Innovation of the Year Award”.
Founded in 1998, MOLOGEN was one of the first German biotech companies to go public. MOLOGEN AG shares are listed on the Prime Standard segment of the Frankfurt Stock Exchange (ISIN DE 0006637200).